论文部分内容阅读
目的分析细胞免疫疗法对不同分期乳腺癌患者体内免疫环境的影响。方法选取2013年3月-2015年3月该院收治的50例乳腺癌患者为研究对象,其中Ⅰ期23例、Ⅱ期15例、Ⅲ期12例,均予以CIK细胞免疫疗法治疗,另选取同期20例体检健康女性为健康组。分析乳腺癌临床病理与CD4~+CD25~+CD127~(low)/Treg及CD4~+CD25~+/Treg表达水平的联系,观察细胞免疫疗法治疗前后患者CD4~+CD25~+CD127~(low)/Treg及CD4~+CD25~+/Treg表达水平的变化。结果治疗前低、中分化程度患者CD4~+CD25~+CD127~(low)/Treg表达水平低于高分化程度患者,淋巴无转移患者CD4~+CD25~+CD127~(low)/Treg表达水平低于有转移患者,差异有统计学意义(P<0.05);低、中分化程度患者CD4~+CD25~+/Treg表达水平低于高分化程度患者,淋巴无转移患者CD4~+CD25~+/Treg表达水平低于有转移患者,差异有统计学意义(P<0.05);治疗后,健康组CD4~+CD25~+CD127~(low)/Treg表达水平低于Ⅰ期、Ⅱ期和Ⅲ期乳腺癌患者,差异有统计学意义(P<0.05);治疗后,健康组CD4~+CD25~+/Treg表达水平低于Ⅰ期、Ⅱ期和Ⅲ期乳腺癌患者,差异有统计学意义(P<0.05)。结论 Treg细胞表达水平与乳腺癌病理分期呈正相关,细胞免疫疗法能够显著降低不同分期乳腺癌患者Treg细胞表达水平,提高机体免疫功能,促进抗肿瘤反应。
Objective To analyze the influence of cellular immunotherapy on immune environment in patients with different stages of breast cancer. Methods Fifty patients with breast cancer admitted to our hospital from March 2013 to March 2015 were selected as study subjects, including 23 cases of stage Ⅰ, 15 cases of stage Ⅱ and 12 cases of stage Ⅲ, all of whom were treated with CIK cell immunotherapy. The same period, 20 cases of healthy women were healthy group. The relationship between the expression of CD4 ~ + CD25 ~ + CD127 ~ (low) / Treg and CD4 ~ + CD25 ~ + / Treg in breast cancer was analyzed. The changes of CD4 ~ + CD25 ~ + CD127 ~ ) / Treg and CD4 ~ + CD25 ~ + / Treg expression. Results The levels of CD4 ~ + CD25 ~ + CD127 ~ (low) / Treg in patients with low and moderate differentiation before treatment were lower than those in patients with well-differentiated lymphoma, and the levels of CD4 ~ + CD25 ~ + CD127 ~ / (P <0.05). The level of CD4 ~ + CD25 ~ + / Treg in patients with low or moderate differentiation was lower than that in patients with well-differentiated lymph node metastasis (P <0.05). After treatment, the expression of CD4 ~ + CD25 ~ + CD127 ~ (low) / Treg in healthy group was lower than that in stage Ⅰ, Ⅱ and Ⅲ (P <0.05). After treatment, the expression of CD4 ~ + CD25 ~ + / Treg in healthy group was lower than that in stage Ⅰ, Ⅱ and Ⅲ breast cancer patients, the difference was statistically significant (P <0.05). Conclusion The expression of Treg cells is positively correlated with the pathological stage of breast cancer. Cellular immunotherapy can significantly reduce the expression of Treg cells in patients with different stages of breast cancer, improve the immune function and promote the anti-tumor response.